Discussion of Zanubrutinib for Adult Patients with CLL/SLL
May 14, 2025 | 2 p.m. EDT
Join NCODA for an in-depth clinical discussion with Dr. John Renshaw on the evolving role of zanubrutinib in the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
This session will explore the therapeutic positioning of zanubrutinib, including its use in patients who are intolerant to other BTK inhibitors, such as ibrutinib and acalabrutinib.
Key learning points include:
-
The clinical role of zanubrutinib in the current CLL/SLL treatment landscape
-
Efficacy and safety data from Study 215, with a focus on patients previously intolerant to ibrutinib and/or acalabrutinib
-
A comparative review of safety profiles between zanubrutinib and acalabrutinib using meta-analyses and matching-adjusted indirect comparisons (MAIC)
-
Dosing strategies and practical approaches to managing adverse events in everyday clinical practice
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Sponsored by
Additional Upcoming Webinars
Upcoming Webinar
Optimizing DLBCL Patient Outcomes with clonoSEQ MRD Monitoring
September 29, 2025 | 2:00 PM
September 30, 2025 | 5:00 PM
Upcoming Webinar
Additional NDC, due to Packaging Change of tivozanib (Fotivda®)
October 3, 2025 | 2:00 PM